- Cann Group (CAN) receives a GMP licence from the Therapeutic Goods Administration (TGA) to manufacture therapeutic goods for its Southern facility
- This licence enables the company to manufacture Active Pharmaceutical Ingredient (API) and medicinal cannabis products under cGMP conditions for supply in Australia and overseas
- Dried cannabis flower products are expected to be available for supply to patients within the next few weeks
- The company advises that its Mildura facility was recently inspected by the TGA in regards to an application for a GMP licence
- Shares are trading 3.64 per cent higher at 28.5 cents each
Cann Group (CAN) has received a GMP licence from the Therapeutic Goods Administration (TGA) to manufacture therapeutic goods for its Southern facility.
This licence enables the company to manufacture Active Pharmaceutical Ingredient (API) and medicinal cannabis products under cGMP conditions at the facility for supply in Australia and overseas.
Dried cannabis flower products are expected to be available for supply to patients within the next few weeks under the TGA’s Special Access Scheme (SAS) and Authorised Prescriber (AP) scheme.
Chief Executive Officer Peter Crock said the licence will enable the company to execute pre-orders.
“Over the last 12 months, we have seen increasing demand for cGMP products from both domestic and international customers and have had pre-orders in place since late last year pending the granting of this licence,” he said.
“We are now able to service the needs of those customers. The granting of this licence is also another important achievement for Cann as we develop our integrated supply chain.”
The company also advised that its Mildura facility was recently inspected by the TGA in regards to an application for a GMP licence.
Once this licence is granted, it will enable the company to manufacture cannabis extract and Cann’s Satipharm CBD capsules.
It will also allow for the company to operate a GMP certified chemical, physical and microbiological laboratory for analytical testing of cannabis dried flower and various medicinal products and excipients.
This will enable Cann to demonstrate that products meet local and overseas regulatory requirements.
Shares were trading 3.64 per cent higher at 28.5 cents each at 2.44 pm AEDT.